Lucas Henrique Moreira
Departamento de Análises Clínicas, Universidade Federal do Paraná (UFPR), Spain
Haoyuan Li
Faculty of Sports and Health Sciences, Guangxi University for Nationalities, Guangxi Nanning,530006, China
ABSTRACT
With the remarkable development of hepatitis C curative medicines over the past decade, the management of viral hepatitis has undergone significant changes. Significant developments have also been made in creating and enhancing the HEV and HAV vaccines. Despite these developments, no medications currently can treat hepatitis B or suppress the virus. The research determines the utility of serum biomarkers in diagnosing. The most promising methods for eliminating the virus are gene-silencing technologies and immunomodulatory therapies. However, targeted antiviral medications against HBV are also encouraging future treatments. Targeted antiviral drugs against HDV have been developed in response to the increasing number of HDV cases; these drugs are currently undergoing clinical trials. Ultimately, the primary objective of eradicating viral hepatitis and reducing the burden of these illnesses on the public health system is to achieve optimal screening through comprehensive testing, widespread immunisation, and treatment coverage. The research recommends conducting more serological studies in conjunction with molecular tests that are specifically designed to produce reactive and definitive results. Furthermore, the manifestation of concurrently positive outcomes signifying the existence of IgM antibodies for distinct causative agents does not preclude the potential for a cross-reaction between them.
Keywords: Serum Biomarkers (SBM), Diagnosing Viral Hepatitis (DSH), Brazil (B).
